FDA Cancer Drug Advisory Committee Votes Down Abbott's Xinlay

Drug Industry Daily
KEYWORDS FDA
A A

An FDA advisory committee has rejected Abbott Laboratories’ experimental prostate cancer drug Xinlay, but the panel agreed the compound has potential and should be further studied.

To View This Article:

Login

Subscribe To Drug Industry Daily